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Rhabdomyosarcomas (RMS) in children and adolescents are heterogeneous sarcomas broadly deﬁned by
skeletal muscle features and the presence/absence of PAX3/7-FOXO1 fusion genes. MicroRNAs are small
non-coding RNAs that regulate gene expression in a cell context speciﬁc manner. Sequencing analyses of
microRNAs in 64 RMS revealed expression patterns separating skeletal muscle, fusion gene positive and
negative RMS. Integration with parallel gene expression data assigned biological functions to 12 co-
expression networks/modules that reassuringly included myogenic roles strongly correlated with
microRNAs known in myogenesis and RMS development. Modules also correlated with clinical outcome
and fusion status. Regulation of microRNAs by the fusion protein was demonstrated after PAX3-FOXO1
reduction, exempliﬁed by miR-9-5p. MiR-9-5p levels correlated with poor outcome, even within fusion
gene positive RMS, and were higher in metastatic versus non-metastatic disease. MiR-9-5p reduction
inhibited RMS cell migration. Our ﬁndings reveal microRNAs in a regulatory framework of biological and
clinical signiﬁcance in RMS.
© 2016 The Author(s). Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Rhabdomyosarcomas (RMS) are the most frequent soft tissue
sarcoma in children and RMS cells resemble those in the early
stages of myogenic differentiation [1,2]. Histologically there are two
major subtypes, embryonal (ERMS) accounting for 60e70% of cases
and alveolar (ARMS). Approximately 70% of ARMS harbor fusion
genes that join the 50 sequence of PAX3 or PAX7 to the 30 sequence of
FOXO1 gene [3,4]. The encoded fusion proteins play an oncogenic
role in the development of ARMS in association with co-operating
events, notably overexpression of MYCN that is a transcriptional
target of the fusion protein and genomically ampliﬁed in approxi-
mately 20% of cases [5e8]. The presence of PAX3-FOXO1 has been
correlated with aggressive clinical behavior in several studies, microRNAs.
.
uthors.
(SIB), Lausanne, Switzerland.
cine Unit, AstraZeneca UK
arch Unit, Centro Nacional
er Ireland Ltd. This is an open acce[9e12] and gene expression proﬁles and genomic imbalances are
similar in fusion gene negative ARMS and ERMS [10,13].
MicroRNAs (miRNAs) are small (20e22 nt) RNA molecules that
can alter cellular processes including proliferation, differentiation
and apoptosis [14]. MiRNAs inhibit protein synthesis of speciﬁc
genes by degrading speciﬁc mRNA species or hindering translation.
Speciﬁc mRNA degradation involves base-pairing to partially
complementary sequences within the 30 UTR [15] or other less
frequently studied mechanisms including their binding to the 50
UTR [16] and gene promoters regions [17]. Each miRNA potentially
regulates hundreds of target gene products and it is suggested that
the entire protein coding genome is regulated by miRNAs [14]. In-
dividual miRNAs have been ascribed oncogenic or tumor suppres-
sor roles in cancer and their roles can clearly be cell context speciﬁc
[18]. Roles for individual miRNAs in RMS have been described such
as miR-1, miR-206, miR-133a/b and miR-378 that maintain an un-
differentiated myogenic state [19e25] andmiR-29 that is described
with a tumor suppressor role [26]. However, a comprehensive view
of how miRNAs shape the gene expression and biological features
of a large number of RMS has not been described but could
contribute to identiﬁcation of prognostic markers/signatures and
ultimately therapeutic targets, as indicated by previous studies of
other tumor types [27e29].ss article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
E. Missiaglia et al. / Cancer Letters 385 (2017) 251e260252Here we derived miRNA expression proﬁling data from high-
throughput sequencing analyses of 64 primary RMS samples and
took a systems biology approach to integrate this with parallel gene
expression proﬁling data. This allowed us to identify co-expression
mRNA networks (modules) with assigned biological functions that
correlated with both patient outcome data and the presence of
PAX3/7-FOXO1. This led us to demonstrate that PAX3-FOXO1 regu-
lates the expression of many miRNAs, including miR-9-5p that was
indirectly altered by PAX3-FOXO1 and shown to be of clinical and
functional relevance.Materials and methods
Primary tumor samples and cell lines
Sixty-four samples (36 ARMS and 28 ERMS) were available from RMS patients as
part of a previously described cohort [30]. Clinico-pathological features of the cases
used in this study for miRNA proﬁling are summarized in Supplementary Table S1A.
Three normal skeletal muscle samples were also obtained. Samples from a similarly
treated cohort of 154 RMS patients were used for miRNA validation analyses and
their clinico-pathological details are summarized in Supplementary Table S1B. RMS
from U.K. centres were collected through the Children's Cancer and Leukaemia
Group (Local Research Ethics Committee protocol Nos. 1836 and 2015 and Multi-
Regional Research Ethics Committee 06/4/71 with consent, where required). Hu-
man cell lines derived from embryonal (RH2, RH36, RD, RMSYM, RUCH2, RUCH3,
CT10) and alveolar (RH3, RH4, RH5, RH18, RH41, RMS, SCMCRMZ, CW9019) were
cultured and validated by DNA ﬁngerprinted as previously described [7,31].Fig. 1. Heatmap based on the expression proﬁle of 161 miRNAs in RMS. Skeletal muscle
contains “muscle speciﬁc” miR-1, miR-133 and miR-206. Myoblast sample is in separate (to
S_PAX7-FOXO1 (dark green), ERMS (sky blue) and ARMS negative (blue). Fusion gene positive
interpretation of the references to color in this ﬁgure legend, the reader is referred to themiRNA library preparation, sequencing and analyses
RNA extraction was performed using Trizol reagent following manufacturer's
instructions (Invitrogen e Carlsbad, CA). Size selection and library preparation was
performed by Fasteris, Plan-les Ouates, Switzerland including duplicates for quality
control using 5 mg of RNA in a maximum volume of 10e15 ml that was sent to the
company. Brieﬂy, small RNA fragments were puriﬁed by acrylamide gel puriﬁcation
and 30 and 50 adapters were ligated to the ends of single stranded small RNA mol-
ecules. Reverse transcription and PCR ampliﬁcation was performed to generate the
DNA colonies template library, which was diluted to 10 nM. The miRNA expression
proﬁling was performed by high-throughput sequencing analysis using a Solexa/
Illumina Genome Analyzer II. The samples were analyzed by grouping in pools of
four per channel. Each sample speciﬁc sequence was then retrieved using a bar-
coding system made of 4 nucleotides. The Solexa fasta-Q format sequence of each
sample was aligned to 2 databases: mature miRNA sequence (miRBase release 21)
and EST (NCBI). The mature miRNA sequence was extended with Ns at each end to
allow the alignment with segments of RNA one or two nucleotides longer than the
wild type sequence. All the alignments were performed using novoalign 2.06.09
with default parameters, after removing the 30 adapter and cutting the sequence to
30 nt. Following alignment, the output ﬁles were imported into R for further anal-
ysis. First of all the sequence with low Solexa quality score (which did not passed the
cut-off in the novoalign software) and those having less than 5 reads in at least 2
samples were ﬁltered out from the analysis. When multiple alignments with the
same score were detected, the sequence was randomly assigned to one of them.
After the alignment each sequence was assigned to an RNA class based on Entrez
Gene type. The variance of the counts data were stabilized using a power trans-
formation function and normalized by applying a non-linear function (lowess).
Differentially expressed miRNAs were identiﬁed by ﬁtting a linear model (limma)
and adjusting for multiple testing by computing FDR values from p-values using the
Benjamini-Hochberg procedure (limma package). Clinical correlations between
levels of miRNA expression and patient outcome data were performed by ﬁtting asamples (red) cluster together showing high expression of a group of miRNA which
mato red). The histology is color-coded as follows: ARMS_PAX3-FOXO1 (khaki), ARM-
(light khaki) and negative (navy) patients mainly cluster into two separate groups. (For
web version of this article.)
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described above. A classiﬁer was generated using pamr package [32].Gene network analysis
RNA gene expression proﬁling data for 64 RMS samples parallel to those proﬁled
for miRNAs were obtained and pre-analyzed as previously described [30]. Probe sets
were ﬁltered in three steps: 1) probe sets with log intensity below 6 across all the
sample were removed; 2) if multiple probe sets per gene were present, only the one
with the highest coefﬁcient of variationwas retained; 3) the ﬁrst 8000 most variable
probe sets associated to a unique entrez ID were selected for further analysis.
The samples underwent Weighted Gene Co-expression Network Analysis
(WGCNA) using the R package version 0.96 [33]. Brieﬂy, a co-expression similarity
measure was calculated by raising the absolute correlation coefﬁcient between
genes to a selected power. Then using a soft thresh-holding procedure an adjacency
matrix was obtained. This was used as distance to generate a hierarchical cluster of
genes. Modules were deﬁned by cutting the breaches using a high cut-off of 0.99 and
a minimum number of genes within the resulting dendrogram equal or above 30.
Enrichment for Gene Ontology terms was evaluated using a hypergeometric test.
The expression of all the genes within each module was summarized as eigengene,
representation of the ﬁrst component was obtained by singular value decomposition
of standardized values. Association between modules expression and clinico-
pathological parameters were evaluated using the Kruskal-Wallis rank sum test
applied to both the eigengene and the gene expression levels. In particular, for theTable 1
Functional annotation, predicted by GeneGo software, of the miR/gene co-expression mo
Module No. of genes Go processes
Black 116 Epidermis development
Ectoderm development
Epithelial cell differentiation
Epithelium development
Blue 516 Cellular macromolecule metabolic process
Regulation of metabolic process
Nucleic acid metabolic process
Regulation of gene expression
Brown 460 Immune system process
Immune response
Defense response
Response to stimulus
Green 206 M phase
Cell cycle phase
Mitosis
Nuclear division
Greenyellow 41 Regulation of atrial cardiomyocyte membrane depolar
Keratan sulfate biosynthetic process
response to nickel ion
multicellular organismal process
Magenta 79 Tissue development
Wound healing
Extracellular matrix organization
Skeletal system development
Pink 103 Extracellular matrix organization
Positive regulation of dendritic spine development
positive regulation of smooth muscle cell chemotaxis
Anatomical structure morphogenesis
Purple 64 Cardiac muscle contraction
Heart contraction
Striated muscle contraction
Muscle contraction
Red 156 Protein localization
Cellular process
Macromolecule localization
Protein transport
Tan 31 Positive regulation of gene expression
Response to external stimulus
Positive regulation of transcription, DNA-dependent
Positive regulation of RNA metabolic process
Turquoise 529 Nervous system development
Developmental process
Anatomical structure development
Multicellular organismal development
Yellow 209 Muscle system process
Muscle contraction
Striated muscle contraction
Myoﬁbril assemblygene expression, the statistical values were obtained by testing the association of
each gene with a speciﬁc parameter and averaged within each module. Therefore,
highmean values of themodule were interpreted as a larger number of geneswithin
that module associated to the parameter tested. Cox's regression model was used to
correlation module expression with patient overall survival (OS) or progression free
survival (PFS). Finally, correlation of miRNA expression levels with the modules was
assessed calculating Pearson correlation considering module eigengenes. MiRNAs
were associated to the modules if they showed an absolute correlation coefﬁcient
above 0.4 and p value < 0.001.Modulating and quantifying miRNA and gene expression
Mir-9-5p knockdown in the RH30 cell line was achieved by transfecting the cells
with miScript miRNA inhibitor using HiPerfect reagent (Qiagen GmbH, Hilden,
Germany). Levels of expression during experiments and analyses of levels in primary
RMS samples were assayed where appropriate using TaqMan® MicroRNA Assays
according to the manufacturer's instructions (Applied Biosystems, CA, USA). Brieﬂy,
RNA was reverse transcribed using TaqMan® MicroRNA Reverse Transcription (RT)
Kit (Applied Biosystems, CA, USA) with speciﬁc-miRNA primers, then the product
used in the real-time PCR reaction in the ABI PRISM 7900HT Sequence Detection
System (Applied Biosystems, CA, USA). Expression data were analyzed by the
comparative threshold cycle (Ct) method accordingly to User Bulletin #2 (Applied
Biosystems). Results were expressed in term of the DCt value and obtained as fol-
lows: DCt miRNA ¼ Average (Ct U6; CtRUN48) e Ct miRNA, where Ct miRNA, Ct U6 anddules for RMS identiﬁed by WGCNA.
GeneGo networks
Immune response_Th17-derived cytokines
Cytoskeleton_Intermediate ﬁlaments
Inﬂammation_Amphoterin signaling
Chemotaxis
Signal Transduction_TGF-beta, GDF and Activin signaling
Signal Transduction_BMP and GDF signaling
Cell cycle_Mitosis
Cytoskeleton_Cytoplasmic microtubules
Inﬂammation _Interferon signaling
Chemotaxis
Cell adhesion_Leucocyte chemotaxis
Immune response Phagocytosis
Cell cycle_Core
Cell cycle_Mitosis
Cell cycle_G2-M
Cytoskeleton_Spindle microtubules
ization Neurophysiological process_Long-term potentiation
Signal transduction_Neuropeptide signaling pathways
Reproduction_FSH-beta signaling pathway
Reproduction_Feeding and Neurohormone signaling
Cell adhesion_Cell-matrix interactions
Cell adhesion_Platelet-endothelium-leucocyte interactions
Development_EMT_Regulation of epithelial-to-mesenchymal transition
Development_Skeletal muscle development
Cell adhesion_Cell-matrix interactions
Proteolysis_ECM remodeling
Development_Cartilage development
Signal Transduction_Cholecystokinin signaling
Muscle contraction
Cytoskeleton_Actin ﬁlaments
Development_Skeletal muscle
Development_Neuromuscular junction
Immune response_Phagosome in antigen presentation
Transcription_mRNA processing
Cell cycle_Mitosis
Development_Hedgehog signaling
Reproduction_Gonadotropin regulation
Immune response_Th17-derived cytokines
Inﬂammation_IL-6 signaling
Cell cycle_G1-S Interleukin regulation
Development_Neurogenesis in general
Development_Hedgehog signaling
Development_Blood vessel morphogenesis
Development_Ossiﬁcation and bone remodeling
Muslce contraction
Development_Skeletal muscle development
Cytoskeleton_Actin ﬁlaments
Cytoskeleton_Regulation of cytoskeleton rearrangement
Fig. 2. Relationship between modules and with other clinic-molecular variables. WGCNA analysis identiﬁed 12 modules based on gene co-expression patterns. Each module
was uniquely color labeled. The expression proﬁle of the genes included in each module was summarized by a module eigengene (ﬁrst principal component of the expression
matrix). These eigengenes were used to assess relationships between modules as well as with other variables A. Hierarchical clustering of module eigengenes and a heatmap
showing the relatedness of these to each other. In the heatmap, red indicates modules are highly related and blue that they are not related. Modules that cluster closer together tend
to be more related. In B. we averaged the statistics computed using the Kruskal-Wallis rank sum test of the genes within each module e higher values indicate the presence of a
larger number of genes contained in that module which are associated to a speciﬁc patient-speciﬁc parameter. The horizontal bars mark the threshold level for signiﬁcance. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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Fig. 3. Heatmap showing the correlation betweenmodule eigengenes in a subset of
miRNAs. The coloredmodules have been labeledwith some features (see Table 1) aswell
as those that correlated with fusion gene positivity (P3/7-F). MiRNAs are indicated in
black at the base and positive and negative correlations with modules indicated in red
and blue, respectively. These were selected based on an absolute Pearson correlation
coefﬁcient above 0.4 and a p value < 0.001. MiRNAs highlighted above the heatmap are
those positively associated with fusion gene positivity (blue), myoMiRs associated with
muscle differentiation (yellow) and miRNAs linked to regulating the cell cycle (green)
(see discussion for further details). (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the web version of this article.)
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endogenous controls U6 and RUN48, respectively. All experiments were performed
in triplicate and differences between groups were evaluated using the Mann-
Whitney test. MYCN expression was modulated using siRNA as previously
described [7]. SiRNA against PAX3-FOXO1 [34] was synthesized by Thermo Fisher
Scientiﬁc (MA, USA) and RH4 cells were transfected with this using Lipofectamine
RNAiMAX (Invitrogen, CA, USA) according to the manufacturer's instructions. Cells
were cultured for 48 h before total RNA and miRNA was extracted using miRNeasy
Mini Kit (Qiagen, Hilden, Germany). To analyze PAX3-FOXO1 levels after RNA inter-
ference, cDNA was synthesized using High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, CA, USA) and quantitative RT-PCR was performed using ViiA™
7 Real-Time PCR System (Applied Biosystems, CA, USA). Primers and probes
designed for analysis of PAX3-FOXO1 were as follows: Forward 50-GAACCCAC-
CATTGGCAAT-30 , Probe 50-CCTCTCACCTCAGAATTCAATTCGTCATAATCTG-30 , Reverse
50-TCTGCACACGAATGAACTTGCT-30 . To analyze miRNA expression after PAX3-
FOXO1 knock-down in RH4 cells, cDNA was synthesized using TaqMan® MicroRNA
Reverse Transcription Kit and Megaplex™ Primer Pools (Applied Biosystems, CA,
USA). Quantiﬁcation of miRNAs was performed on TaqMan® Array Human Micro-
RNA AþB Cards Set v3.0 using ViiA™ 7 Real-Time PCR System according to the
manufacturer's instructions and analyzed with ViiA™ 7 Software (Applied Bio-
systems, CA, USA).
Migration and viability assays
At 72 h post transfection, cells were re-suspended in DMEM plus 1% FCS and
placed in triplicate into cell culture inserts (BD, NJ, USA) before being submerged
into specially adapted 24 well plates (BD, NJ, USA) containing DMEM plus 10% FCS.
24 h later, cells that had not migrated were removed using a cotton bud, and cells
that had migrated to the base of the inserts were ﬁxed overnight in 100% methanol
at 20 C and then stained for 2 min with 2% crystal violet solution (Sigma-Aldrich,
MO, USA). Cells were photographed at 10 magniﬁcation using a Leica DM IRB
microscope with a Leica 420C camera attached (Leica Microsystems, Milton Keynes,
UK) (4 ﬁelds of view) and counted manually in photoshop CS3. Viability was
assessed at 72 h post transfection using Cell Titer Aqueous ONE reagent (Promega,
WI, USA) as previously described [7].
Results
miRNA proﬁles in skeletal muscle and RMS
MiRNA expression proﬁling was performed by high-throughput
sequencing analysis of 68 samples (3 skeletal muscle, 1 myoblast
and 64 RMS patient samples (Supplementary Table S1)). On
average, around 2,069,412 tags were sequenced for each sample
(range: 753,614e7,390,288). After sequence alignment and
ﬁltering, each tag was assigned to a RNA class based on Entrez Gene
type and 78% and 73% were shown to be miRNAs in RMS and
skeletal muscle, respectively, conﬁrming their successful enrich-
ment (Supplementary Fig. S1A). Since miRNAs are often included in
transcription clusters, their expression is more coordinated when
located in close proximity compare to those further apart [35]. This
featurewas clearly observed in our dataset (Supplementary Fig.1B).
Direct comparisons of levels of expression across molecular
(fusion positive versus negative RMS), histological (skeletal muscle
versus RMS), and clinical (metastatic M1 versus nonmetastatic M0)
entities produced lists of miRNAs signiﬁcantly over or under-
expressed in these groups (Supplementary Tables S2-5). Correla-
tion between miRNA expression and overall survival (OS) and
progression free survival (PFS) was also assessed by Cox propor-
tional hazard regression model (Supplementary Tables S6-9).
miRNA proﬁle distinguishes RMS according to fusion gene status
Unsupervised hierarchical clustering analysis performed using
miRNAs with at least 100 tags in 50% of the samples showed the
presence of distinct patterns of expression across RMS samples
(Fig. 1). Notably, miRNA expression patterns mostly distinguished
RMS histological subtypes showing sets of miRNAs positively and
negatively associated with fusion gene status. The well-known
muscle speciﬁc miRNAs including miR-1, miR-133 and miR-206
showed higher expressed in skeletal muscle versus RMS subtypes.Application of class prediction analysis based on nearest
shrunken centroid classiﬁer [32] showed that miRNA expression
can distinguish fusion positive and negative patients with around
89% accuracy (Supplementary Fig. S2) using the expression level of
Fig. 4. Validation of clinical correlations. A. Validation of NGS results on larger cohort of RMS. Box and whisker plots representing the expression levels (QRT-PCR) of miR-9 in 13
normal skeletal muscles, 66 ERMS, 31 ARMS fusion negative (ARMS_NEG), 45 ARMS PAX3-FOXO1A (ARMS_P3F), 12 ARMS PAX7-FOXO1A (ARMS_P7F), 8 ERMS cell lines (CL_ERMS),
8 ARMS cell lines (CL_ARMS) and 2 myoblast samples (Myoblasts). B. Silencing of MYCN using siRNAs resulted in a reduction in the expression level of miR-9 in RH30 cells when
compared to control cells. Data represent a triplicate measurement for each sample at 72 h post addition of negative control and MYCN siRNAs. **p < 0.01; ***p < 0.001.
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Table 2
MiRNAs in modules associated with fusion genes, differential expressed between fusion positive versus negative RMS and fold change reduction by decreasing PAX3-FOXO1.
MiRNA Turquoise module
(Pearson correlation
coefﬁcient)
Purple module
(Pearson correlation
coefﬁcient)
log2 fold
change expression
fusion positive vs
negative RMS
RH4 set 1 fold
expression relative
to non targeting control
RH4 set 2 fold
expression relative
to non targeting control
miR-9-5p 0.67 0.51 1.14 2.49 1.15
miR-660-3p 0.64 0.41 0.53 3.54 1.22
miR-9-3p 0.70 0.53 1.32 1.42 1.32
miR-532-3p 0.67 0.49 0.46 1.40 1.37
miR-135a-5p 0.57 0.45 1.45 13.01 8.85
miR-193b-5p 0.58 0.19 0.43 3.18 2.14
miR-362-5p 0.72 0.51 0.28 4.98 1.28
E. Missiaglia et al. / Cancer Letters 385 (2017) 251e260 25711 miRNAs. These data suggest a strong interplay between fusion
protein and miRNA expression that potentially contributes to the
malignant phenotype of RMS.
RMS gene co-expression-modules are assigned biological functions
and correlate with clinicopathological features
Based on the principle that co-expressed genes are commonly
associated with similar biological function/pathways, we employed
WGCNA using parallel gene expression data from the 64 RMS pa-
tients [30] and identiﬁed 12 groups of co-expressing genes/mod-
ules. Each module was color coded and tested for GO term
enrichment in order to associate each module with biological
functions (Table 1). Consistent modular gene structure was also
seen using a larger population of 132 publicly available RMS sam-
ples [13] suggesting that these modules are a good representation
of the biological characteristic of RMS tumors (data not shown). In
addition, an eigengene per module was generated for each patient
to summarize the expression of all the genes contained in each
module. These values were used to correlate modules to each other
as well as to clinico-pathological features (Fig. 2). Modules did not
show signiﬁcant correlation with IRS stage, metastasis, tumor size
or age of patient at diagnosis (data not shown). However notably,
the turquoise, green/yellow, pink and purple modules showed a
signiﬁcant correlation fusion status and histological subtype
(Fig. 2B). The association between modules and overall survival
(OS) or progression free survival (PFS) was also tested. The pink and
turquoisemodules showed a signiﬁcant correlationwith the OS and
PFS (Supplementary Table S10).
RMS gene-expression-modules associated with skeletal muscle
development correlate with known myomiRs
As miRNAs are known to modulate many of their targets
through mRNA transcript degradation [14,36], we correlated the
expression of miRNAs to the module eigengenes in order to eval-
uate their level of association. Fig. 3 represents a heatmap of the
correlation between module eigengenes and a subset of miRNAs
selected based on their coefﬁcient values (absolute value above 0.4)
and signiﬁcance (p value < 0.001). The power of this approach is
demonstrated by well-known myogenic miRs (myomiRs) -1, -206
and -133a that are most highly expressed in more differentiated
skeletal muscle. These myomiRs correlated positively with yellow
(miR-1, direct pearson (DP) 0.59; miR-206, DP 0.49; miR-133a, DP
0.58), and purple modules (miR-1, DP 0.73; miR-206, DP 0.46; miR-C. Kaplan-Meier plots for miR-9 expression and overall survival (OS) Expression levels with
between the second and third quartile (>Q25 and < Q75) and ‘High’ when within the top
survival for each patient group, the CI-95% values and pairwise comparison p values are sho
miR-9 expression in overall survival (OS). Bone-marrow metastasis at diagnosis (predictive
An HR value greater than 1 indicates a predictive factor. HR, Hazard Ratio; CI, Conﬁdence
RH30. F. This signiﬁcantly reduces the ability of the cells to migrate in a transwell assay (***p133a, DP 0.70) (Fig. 4). In an inverse manner, miR-221 and -222 are
myoD-associated myomiRs most highly expressed early in
myogenic differentiation [37] and show a negative correlations
with the yellow and purple modules (miR-221, DP-0.24, -0.043;
miR-222, DP-0.2, -0.041, respectively). Bothmodules had functional
annotations linked to skeletal muscle development. Additionally
miR-1 and -133a showed inverse correlation with green module
(miR-1, DP-0.31; miR-133a, DP-0.37) that was linked to cell cycle,
indicating that low levels of these myomiRs correlated with genes
involved in cell cycle progression. These myomiRs/gene expression
correlations associated with differentiation processes strongly
support the ability of the approach to identify key roles for miRNAs
in RMS.
PAX3-FOXO1 alters the proﬁle of miR expression
Consistent with miRNA expression accurately distinguishing
fusion positive from negative patients, four of the 12 modules
correlated with fusion gene positivity (turquoise, purple, green/
yellow, and pink) with turquoise correlating most strongly (Fig. 2B
and indicated in Fig. 3). MiRNAs were also overexpressed in PAX3/
7-FOXO1 positive cases compared to RMS without the fusion gene
(Supplementary Table S3). Based on these results, we hypothesized
that the fusion protein could regulate miRNA expression. To iden-
tify miRNAs altered by PAX3-FOXO1, RNA interference (RNAi) was
used to reduce expression levels of the fusion gene in the cell line
RH4 (Supplementary Fig. S3A), and corresponding miRNAs levels
screened for in duplicate (Supplementary Table S11). To prioritize
miRNAs of likely relevance in RMS patients for further investigation
we identiﬁed those that were reduced by knockdown of the fusion
protein, were most strongly positively correlated with the tur-
quoise and purple modules and that were also differentially over-
expressed comparing fusion gene positive with negative RMS. This
identiﬁed miRNAs as candidates for further investigation (Table 2),
including miR-9-5p that was additionally correlated with meta-
static behavior and poor outcome (Supplementary Tables S4-S9).
Validation of MiR-9-5p levels in RMS driven by PAX3-FOXO1 via
MYCN
miR-9-5p expression levels were analyzed by quantitative RT-
PCR in a larger cohort of RMS patients (n ¼ 154, Supplementary
Table S1B) and, consistent with the sequencing data
(Supplementary Table S3), results showed that levels of miR-9-5p
were signiﬁcantly higher in fusion gene positive versus negativein the ﬁrst quartile was considered ‘Low’ (<Q25), ‘Intermediate’ when expression was
quartile (>Q75). p values were obtained using Log-Rank test (Mantel-Cox). Median
wn on each graph. D. A forest plot showing the multivariate analysis (MVA) results of
factor in univariate analysis) was incorporated in to the Cox regression model for OS.
Interval. E. Synthetic miR-9 inhibitors reduce miR-9 expression levels in the cell line
< 0.001) but G. had no detectable effect on cell viability, as assessed by the MTS assay.
E. Missiaglia et al. / Cancer Letters 385 (2017) 251e260258RMS (Wilcoxon test p < 0.0001), skeletal muscle and myoblasts
(Wilcoxon test p < 0.0001) (Fig. 4A). In addition, fusion gene pos-
itive RMS cell lines had signiﬁcantly higher miR-9-5p levels than
ERMS cell lines (Wilcoxon test p ¼ 0.04) (Supplementary Fig. S3B).
As miR-9-5p levels decreased by reducing PAX3-FOXO1 expres-
sion (Table 2, Supplementary Table S11), we examined available
data for PAX3-FOXO1 [38] and MYCN (Walters et al. unpublished)
DNA binding sites near the miR-9-5p locus in RMS. No sites were
identiﬁed for PAX3-FOXO1 but MYCN binding sites were found
consistent with those reported for MYC and MYCN in neuroblas-
toma [39]. Based on MYCN being a downstream transcriptional
target of PAX3-FOXO1 [5,38], we also tested the effects of
decreasing MYCN levels on miR-9-5p levels in a PAX3-FOXO1
positive cell line. MiR-9-5p levels were signiﬁcantly decreased by
MYCN reduction (Fig. 4B). Therefore, PAX3-FOXO1 regulates miR-9-
5p levels via MYCN in RMS.
MiR-9-5p levels correlate with poor patient outcome, metastases
and cell migration in fusion positive ARMS
Modules associated with the PAX3-FOXO1 fusion genes (tur-
quoise and purple) positively correlated with miR-9-5p expression.
Signiﬁcantly higher levels of miR-9-5p expression were noted in
metastatic versus non-metastatic considering both all RMS and
fusion positive RMS (Supplementary Tables S4 and S5). Signiﬁ-
cantly lower OS and PFS in all RMSwas associated with highmiR-9-
5p expression (Supplementary Tables S6 and S8) and also within
fusion positive RMS cases (Supplementary Tables S7 and S9). Uni-
variate analyses, including only PAX3-FOXO1 cases, also revealed
signiﬁcant correlations with outcome (Supplementary Table S12),
although the sample size was very limited.
Univariate analyses of the quantitative RT-PCR data for the
second validation cohort (n¼ 154, Supplementary Table S1B) using
a Cox regression model with miR-9-5p as a continuous variable
revealed signiﬁcant correlations in fusion gene positive RMS with
OS (p ¼ 0.037, HR ¼ 1.242, CI 95% 1.013e1.522) and PFS (p ¼ 0.034,
HR ¼ 1.239, CI 95% 1.016e1.511). In PAX3-FOXO1 cases (n ¼ 45), a
signiﬁcant correlation with OS was also observed (p ¼ 0.012,
HR ¼ 1.445, CI 95% 1.084e1.925) and a trend with PFS (p ¼ 0.055,
HR ¼ 1.29, CI 95% 0.995e1.676). No correlations with miR-9-5p
levels and survival were observed in fusion gene negative pa-
tients (OS; p ¼ 0.65, HR ¼ 0.971, CI 95% 0.853e1.104. PFS; p ¼ 0.65,
HR ¼ 0.994, CI 95% 0.853e1.104). Kaplan-Meier analyses were
consistent with these results: log-rank test identiﬁed signiﬁcant
correlations with both OS (p ¼ 0.003) (Fig. 4C) and PFS (p ¼ 0.004)
(Supplementary Fig. 3C) when RMS fusion positive patients
(n¼ 57) were split into three groups based on their levels of miR-9-
5p expression (percentiles 0e33%, 34e66%, 67e100%). When the
highest miR-9-5p expressers were compared to the lowest in
multivariate analysis (MVA), miR-9-5p retained its independent
predictive value for OS (p ¼ 0.028, HR ¼ 4.4, CI 95% 1.2e16.6)
(Fig. 4D) and PFS (p ¼ 0.012, HR ¼ 3.74, CI 95% 1.34e10.44)
(Supplementary Fig. S3D). When MVA analyses was repeated
considering only the 45 PAX3-FOXO1, high miR-9-5p expression
remained an independent predictive variable correlating with
outcome (p¼ 0.004, HR¼ 4.55, CI 95% 1.63e12.76) correlating with
outcome.
Due to the signiﬁcant correlations of high miR-9-5p levels with
metastatic disease and poor survival as well as strong negative
correlations with a module associated with processes in cell
adhesion (pink module) (Fig. 3), we tested whether miR-9-5p
functionally inﬂuenced the migratory behavior of RMS cells. Cell
migration in the RH30 cell line was assessed 72 h after transfection
with a synthetic inhibitor against miR-9-5p by placing cells into a
transwell migratory assay for 24 h. At the end point of experiments,levels of miR-9-5p were decreased on average by 70% compared to
control treated cells (Fig. 4E). There was signiﬁcant reduction in
levels of migration in cells with reduced miR-9-5p levels versus the
controls (p < 0.001, Fig. 4F) but no effect was on cell viability, as
assessed by the MTS metabolic assay (Fig. 4G).
Discussion
Here we describe the sequencing analyses of miRNAs in a large
series (n ¼ 64) of well-characterized RMS samples. We were
broadly able to distinguish tumor from skeletal muscle and also
fusion gene positive from fusion gene negative RMS. This is
consistent with a previous study of sarcomas that included only 7
RMS cases in which cluster analyses of miRNA data separated
skeletal muscle from RMS and other types of sarcoma and placed 3
alveolar RMS in a different group from one embryonal case and 3
adult pleomorphic cases [40]. Furthermore, our integrated analyses
of miRNA expression data with parallel gene expression levels us-
ing WCGNA identiﬁed co-expression modules that we were able to
assign with biological functions and also correlate with clinical
outcome data and fusion gene status. Given that miRNAs regulate
the expression of many genes in a dynamic and cell context speciﬁc
manner [14], these results provide a valuable framework and
resource for further investigations of RMS.
Reassuringly, modules identiﬁed as associated with skeletal
muscle development (Fig. 3) included correlations with miRNAs
that have been previously described as miRNAs involved in myo-
genesis (myomiRs) and also shown to functionally impact on the
phenotype of RMS cell lines. Speciﬁcally these included miRs -1,
-206, -133a and miR-378 that correlated positively with muscle
associated modules (yellow and purple, Table 1, Fig. 3) [19e25]. In
addition, we previously showed that lower levels of miR-206
expression correlated with poorer outcome in samples from RMS
patients that was linked to their undifferentiated myogenic
phenotype, indicating relevance to the clinical behavior of patients
[22]. MiR-221 andmiR-222 are also described asmyomiRs and their
overexpression and reduction is reported to enhance and decrease
myoD protein levels, respectively [37]. As predicted from this, our
analyses of miRs-221-3p and -222-3p inversely correlated their
expression with the skeletal muscle associated modules (yellow
and purple) in contrast to miRs -1, -133 and -378 which were
positively correlated to these functional modules. MiR-128-3p
shows a similar expression pattern in these modules to miRs -1,
-133 and -378 and is described with a clear role in muscle devel-
opment [41]. A deﬁnitive role for miRs -221, -222 and 128-3p in
RMS remains to be determined, as well as other miRNAs correlated
with the modules deﬁned with myogenic functions, such as miR-
96-3p, miR-152-3p and miR-156-5p.
Interestingly, miR-1, 133, 206, 378 and 128-3p negatively, and
miR-221 and -222 positively, correlated with gene expression
processes for cell adhesion, chemotaxis and extracellular organi-
sation (pink module). This is consistent with the differentiation
status of RMS cells shown in oncogenic KRAS (G12D) induced
zebraﬁsh models of RMS where embryonal RMS cells recapitulate
normal myogenesis and their associated migratory and prolifera-
tive capacity [42]. Also, targets of these miRNAs in these networks
are likely to contribute to these invasive and migratory phenotypes
in RMS, for example miR-206 targets the MET tyrosine-kinase re-
ceptor which is highly expressed in RMS and enhances RMS cell
migration [24]. Similarly, miR-221 and -222 have strong evidence to
support that they target TIMP3 and MMP1 proteins known to in-
ﬂuence the extracellular matrix (http://mirtarbase.mbc.nctu.edu.
tw/index.php).
The myomiRs -1, -133a and miR-378 also inversely correlated
with modules linked to cell cycle progression (green and red),
E. Missiaglia et al. / Cancer Letters 385 (2017) 251e260 259consistent with their role in cell cycle arrest when overexpressed in
RMS [21,23] and the requirement of this prior to normal myogenic
differentiation [43]. These cell cycle related modules were posi-
tively correlated with other miRNAs that may play a role in RMS,
including miR-106b, that is overexpressed and associated with
proliferation in medulloblastoma [44], miR-32 that when down-
regulated in mesenchymal stem cells inhibits cell cycle progres-
sion [45] and miR-130b that enhances proﬁleration through inac-
tivating HIPPO signaling in gliomas [46]. Mir-19a-3p, as part of the
polycistronic miRNA cluster miR-17-92, also positively correlated
with these cell cycle modules as well as a module associated with
fusion genes (turquoise). The latter and red modules were both
linked to Sonic hedgehog (SHH) signaling. Together this is consis-
tent with high expression of the miR17-92 cluster being genomi-
cally ampliﬁed in around 20% of RMS and MYCN driven, mostly in
those with PAX7-FOXO1 fusion genes, and possible involvement of
the cluster in proliferation through SHH signaling [47,48].
The strongest positive and negative correlations between genes
and miRNA expression levels were associated with fusion gene
positive RMS cases (Figs. 2 and 3). In addition, the turquoise and
pink modules linked to fusion gene positivity were also most
signiﬁcantly associated with poor outcome (Supplementary
Table S10). This is consistent with several studies, including our
own, demonstrating the prognostic value of the presence of a
fusion gene in RMS [9e12]. Our analyses indicates that the fusion
protein impacts on the expression of miRNAs and through
screening changes to miRNA levels following reduction of PAX3-
FOXO1 expression in a cell line, we were able to show that the
fusion protein alters the expression levels of microRNAs. Interest-
ingly, miR-9-5p was one of the top hits in the screen, was highly
correlated with the modules associated with the presence of the
fusion gene and it was more highly expressed in fusion gene pos-
itive RMS compared to fusion gene negative RMS (Table 2).
Although no PAX3-FOXO1 binding sites were identiﬁed nearmiR-9-
5p, we showedmiR-9-5p to be indirectly driven by PAX3-FOXO1 via
MYCN. MYC/MYCN have previously been shown to bind to the miR-
9 locus and activate expression in other cell types [39]. MYCN is
known to be a direct transcriptional target of the fusion protein [5]
and to operate in a positive feedback loop mechanism [7]. This
overlap in miRNA targets for PAX3-FOXO1 and MYCN is to the gene
expression changes identiﬁed through altering MYCN levels [7] and
PAX3-FOXO1 expression in RMS that show considerable overlap
[13]. Taken together, this indicates that the fusion protein together
with MYCN, and other transcription factors downstream of PAX3-
FOXO1, such as MYOD1, regulate the expression of miRNAs and
their many target genes, to massively re-programme gene expres-
sion in RMS cells towards a tumorigenic phenotype [49]. The
contribution of these altered levels of miRNAs is predicted to
impact on the phenotype of fusion positive RMS in ways that
include the developmental, myogenic, immunological and cell
adhesion processes indicated in the co-expression modules (Fig. 3).
As representative of a miRNA associated with the presence of
PAX3-FOXO1, miR-9-5p levels are shown to contribute to the clin-
ical and biological behavior of RMS. MiR-9-5p levels were higher in
metastatic versus non-metastatic cases and correlated with a poor
outcome of patients, including within fusion gene positive group.
Through reducing miR-9-5p we deduce a role for miR-9-5p in
enhancing RMS cell migration and this cellular phenotype poten-
tially facilitates metastastic behavior. This is similar to the roles for
miR-9-5p in the proliferation, differentiation and migration of
neural progenitor cells but miR-9-5p may alter different gene tar-
gets dependent on cell context [50]. Also, aberrant miR-9-5p levels
have been indicated in several cancer types where it may be either
overexpressed or underexpressed. Overexpression has been
described in Hodgkin's lymphoma [51], brain tumors [52],neuroblastoma [39] and gastric cancers, in the latter affecting
proliferation via the miR-9 target CDX2 [53]. Reduced levels of miR-
9-5p play a role in ovarian cancer cells where this, in part, enhances
cell proliferation through NFkappaB1 [54]. Furthermore, in normal
epithelial and breast cancer cells, miR-9-5p induces epithelial to
mesenchymal transition by targeting E cadherin (CDH1) [39].
Recently, reducing miR-9-5p in an osteosarcoma cell line and
identiﬁcation of high levels of expression in primary tumors sug-
gests a role for this miRNA in regulating the progression of osteo-
sarcoma [55]. This role in osteosarcomas in addition to RMS
described here, indicates a role for miR-9-5p in mesenchymal
malignancies further to that previously described epithelial and
neural cancers.
MiRNAs altered by the fusion protein, including indirectly miR-
9-5p (Table 2, Supplementary Tables S3 and S11), are likely to play
an important role in RMS. Furthermore, the expression levels and
the functional framework presented have assigned likely functions
for miRNAs in RMS for further investigation. These could identify
additional tumor biomarkers and, depending on their expression in
bodily ﬂuids, useful markers for disease monitoring, as exempliﬁed
by the detection of the myomiR miR-206 in serum from RMS pa-
tients [56]. Achieving good in vivo delivery for therapeutically tar-
geting or introducing miRNAs has potential but is still challenging
[29]. However, further understanding of miRNAs in RMS may ulti-
mately enable targeting their key roles via regulation of multiple
genes and pathways in ways that could improve outcome for
patients.
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